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TRANSLATIONAL RELEVANCE 
 
It is now appreciated that the tumor microenvironment, in particular the tumor inflammatory 
cell infiltrate and tumor-associated stroma, is an important determinant of disease progression 
and outcome in colorectal cancer.  Of interest it has been shown that assessment of such 
characteristics using routine pathological specimens, using for example the Klintrup-
Mäkinen grade and tumor stroma percentage, has prognostic utility independent of current 
pathological staging.  However, whether such measures may be combined to increase their 
clinical utility is unknown.  In the present study, a novel, cumulative prognostic score based 
on these tumour microenvironment characteristics is described. This score, utilising routine 
pathological specimens and termed the Glasgow Microenvironment Score, is shown to have 
prognostic utility independent of lymph node involvement, venous invasion and mismatch 
repair status.  Furthermore, given its reliance on routine specimens, the Glasgow 
Microenvironment Score may be readily evaluated and validated. 
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Abstract 
Purpose 
The tumor microenvironment is recognised as an important determinant of 
progression and outcome in colorectal cancer (CRC).  The aim of the present study was to 
evaluate a novel tumor microenvironment-based prognostic score, based on histopathological 
assessment of the tumor inflammatory cell infiltrate and tumor stroma, in patients with 
primary operable CRC. 
Experimental Design 
Using routine pathological sections, the tumor inflammatory cell infiltrate and stroma 
were assessed using Klintrup-Mäkinen (KM) grade and tumor stroma percentage (TSP) 
respectively in 307 patients who had undergone elective resection for stage I-III CRC.  The 
clinical utility of a cumulative score based on these characteristics was examined. 
Results 
On univariate analysis, both weak KM grade and high TSP were associated with 
reduced survival (HR 2.42, P=0.001 and HR 2.05, P=0.001 respectively).  A cumulative 
score based on these characteristics, the Glasgow Microenvironment Score (GMS), was 
associated with survival (HR 1.93, 95% CI 1.36-2.73, P<0.001), independent of TNM stage 
and venous invasion (both P<0.05).  GMS stratified patients in to three prognostic groups: 
strong KM (GMS=0), weak KM/low TSP (GMS=1), and weak KM/high TSP (GMS=2), with 
five-year survival of 89%, 75% and 51%, respectively (P<0.001).  Furthermore, GMS in 
combination with node involvement, venous invasion and mismatch repair status further 
stratified five-year survival (92% to 37%, 93% to 27% and 100% to 37%, respectively). 
 
  
 
4
Conclusions 
The present study further confirms the clinical utility of assessment of the tumor 
microenvironment in CRC and introduces a simple, routinely available prognostic score for 
the risk stratification of patients with primary operable CRC. 
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INTRODUCTION 
Colorectal cancer remains the second most common cause of cancer death in North 
America and Western Europe (1).  At present, prognosis and the need for adjuvant therapy is 
primarily based on pathological assessment of the depth of primary tumor invasion and the 
presence of lymph node metastases (2), however, there is clear heterogeneity in the survival 
of patients with similar disease stage, particularly those with Stage II (locally advanced, 
lymph-node negative) disease (3).   
Although several high-risk pathological characteristics, such as venous invasion or 
serosal involvement, are now recognised as important determinants of survival, particularly 
in node negative disease (4, 5), it is now clear that other host and tumor characteristics may 
similarly determine oncological outcome.  Indeed, alongside the intrinsic properties of tumor 
cells, components of the tumor microenvironment, such as tumor-infiltrating immune cells 
(6), and the tumor-associated stroma (7), may also determine disease progression and the 
outcome of patients with colorectal cancer.   
Increased survival in association with peritumoral inflammatory responses was first 
reported in patients with colorectal cancer almost fifty years ago (8).  To date, over one 
hundred individual studies have found a reduction in disease recurrence and an increase in 
survival in association with a conspicuous local inflammatory cell infiltrate in patients with 
colorectal cancer (6).  Although many studies have examined the impact on outcome of 
individual inflammatory cell subtypes and their density and location within the tumor 
microenvironment, it is now clear that semi-quantitative, histopathological assessment of the 
generalised inflammatory infiltrate using routine pathological specimens, such as that offered 
by the Klintrup-Mäkinen grade, not only correlates with the density of individual 
inflammatory cell subtypes, but also provides similar prognostic detail (9-12).  
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Similarly, extensive characterisation of the tumor-associated stroma, predominantly 
comprising of cancer-associated fibroblasts and extracellular matrix, has identified pertinent 
roles in facilitating tumor growth and invasion (13), angiogenesis (14, 15) and energy 
homeostasis (16).  Of interest however, it has been reported, again using routine pathological 
specimens, that a high stroma to tumor ratio is associated with the presence of adverse 
pathological characteristics (17).  Furthermore, the presence of a high tumor stroma 
percentage has been validated as a stage-independent marker of reduced survival in patients 
with primary operable colorectal cancer (17-19) and may also identify patients less likely to 
benefit from adjuvant 5-fluorouracil-based chemotherapy (17). 
Of interest, although both hold independent prognostic value for patients with primary 
operable colorectal cancer (17), combined assessment of the tumor inflammatory cell 
infiltrate and tumor stroma, and subsequently the interaction and combined impact on 
survival, has not previously been examined.  This therefore presents the opportunity to 
develop a tumor microenvironment score which may provide prognostic information 
complimentary to current pathological assessment of features of the tumor itself.  The aim of 
the present study was to evaluate a novel, tumor microenvironment-based prognostic score in 
patients with primary operable colorectal cancer. 
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PATIENTS AND METHODS 
 
 Since 1997, all elective and emergency colorectal cancer resections taking place at a 
single surgical unit in Glasgow Royal Infirmary have been entered in to a prospectively 
maintained database.  For the present study, patients who, on the basis of pre-operative 
computed tomography and findings at laparotomy were considered to have undergone 
potentially curative, elective resection for stage I-III primary colorectal adenocarcinoma 
between January 1997 and May 2008 were included.  Patients who had undergone 
neoadjuvant therapy, emergency resection or resection with palliative intent, or had died 
within 30 days of surgery were excluded.  Local ethics committee approval was granted. 
 Clinicopathological characteristics 
 Patient demographics were collected prospectively and tumors were staged using the 
fifth edition of the AJCC/UICC-TNM staging system (2).  Additional pathological data were 
taken from reports issued following resection.  Since 2003, elastica staining has been used in 
our institution for the detection of venous invasion, with tumors prior to 2003 stained 
retrospectively (5).  Both intramural and extramural invasion were considered as evidence of 
venous invasion.  Margin involvement was considered as involvement of any non-
peritonealised surgical margin, including the circumferential resection margin.  Following 
surgery, patients were discussed at an institutional multi-disciplinary meeting; patients with 
stage III or stage II disease with high-risk pathological features and without co-morbid 
disease precluding adjuvant therapy were considered for primarily 5-fluorouracil-based 
chemotherapy. 
Assessment of mismatch repair status 
Mismatch repair (MMR) status was assessed for a subset of patients who were 
included in a previously constructed colorectal cancer tissue microarray (TMA) (20).  TMA 
  
 
8
slides were placed in the ThermoFisher pH 9 PT module solution (Thermo Fisher Scientific 
Inc., Waltham, MA, USA) at room temperature.  Slides were then heated in the PT module to 
a temperature of 96oC for 20 minutes and allowed to cool.  Using the ThermoFisher 
autostainer, slides were incubated in peroxidase block for 5 minutes and rinsed with TBS.  
They were then incubated in UV protein blocker for 5 minutes and rinsed once again with 
TBS solution.  Slides were then incubated in primary antibody for 20 minutes at a 
concentration of 1:100 for MLH1 and MSH6 and 1:50 for MSH2 and PMS2 (product codes: 
M3640, M3646, M3639 and M3647 respectively; Dako UK Ltd, Cambridgeshire, UK).  
Following this incubation period, slides were rinsed with TBS and Quanto Amplifier was 
applied to slides for 10 minutes followed by a further wash with TBS.  Quanto Polymer was 
then added for 10 minutes followed by a TBS wash.  DAB Quanto substrate was then added 
for 5 minutes, slides washed in TBS, counterstained in haematoxylin, blued in Scotts’ tap 
water, dehydrated through a series of graded alcohols and cover slips applied with DPX.  
Mismatch repair protein expression was established by a single observer (A.G.P) 
blinded to clinical outcomes using UK NEQAS scoring guidelines.  Appendix and normal 
colon were used as positive controls.  Accuracy of expression was determined by (i) strong 
nuclear expression in immune cells, (ii) strong nuclear expression in the base and lower half 
of the crypts with fading of intensity near the top of the crypt adjacent to the luminal surface 
and (iii) strong staining in lymphoid follicles.  An observer blinded to clinical outcome 
(J.H.P) scored 10% of cores.  
 Expression was reported as MMR proficient (strong nuclear staining with positive 
immune cells), or MMR deficient (staining intensity is either weak or patchy with normal 
immune cell infiltrate, or negative with complete loss of expression and normal immune cell 
expression).  Peri-nuclear immunopositivity was not considered diagnostic for protein 
expression.  Patchy staining of the cytoplasm with normal immune cell expression was 
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considered to be a result of MMR protein complex destabilisation and loss of binding to 
nuclear DNA.  
Assessment of the tumor microenvironment 
 Routine haematoxylin & eosin-stained sections of the deepest point of tumor invasion 
were retrieved.  Two investigators (C.H.R and C.S.D.R), trained by a consultant colorectal 
pathologist and who were blinded to clinical outcomes, assessed the generalised 
inflammatory infiltrate semi-quantitatively according to Klintrup-Mäkinen grade as 
previously described (21, 22).  Briefly, using haematoxylin & eosin-stained sections of the 
deepest point of tumor invasion, inflammatory cell density at the invasive margin was graded 
using a four-point scale and subsequently classified as low-grade (no increase or mild/patchy 
increase in inflammatory cells) or high-grade (prominent inflammatory reaction forming a 
band at the invasive margin, or florid cup-like infiltrate at the invasive edge with destruction 
of cancer cell islands) (Figure 1a-b). 
 As previously described, tumor stroma percentage was assessed semi-quantitatively 
by a single investigator (J.H.P) blinded to clinical outcomes (17).  Briefly, using full sections 
of the deepest point of tumor invasion, the proportion of stroma was calculated as a 
percentage of the visible field, excluding areas of mucin deposition or necrosis.  Tumors were 
subsequently graded as low tumor stroma percentage (≤50%) or high tumor stroma 
percentage (>50%) (Figure 1c-d).  Co-scoring of 10% of tumors was performed by a second 
investigator (C.S.D.R) to ensure consistency.  The interobserver intraclass correlation 
coefficient was 0.81 for assessment of both Klintrup-Mäkinen grade and tumor stroma 
percentage group  (>0.7 is considered good).  Any discrepancies for the assessment of either 
Klintrup-Mäkinen grade or tumor stroma percentage group were resolved by discussion 
between the two investigators to reach a consensus opinion. 
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Survival 
Patients were routinely followed up for five years following surgery.  Date and cause 
of death were crosschecked with the cancer registration system and the Registrar General 
(Scotland).  Death records were complete until 15th March 2013 that acted as the censor date. 
Cancer-specific survival was measured from date of surgery until date of death from 
colorectal cancer. 
Statistical analysis 
The relationship between clinicopathological and tumor microenvironment 
characteristics and survival was examined using univariate Cox proportional hazards 
regression to calculate hazard ratios (HR) and 95% confidence intervals (95% CI).  Variables 
with P-value <0.1 on univariate regression analysis were then examined in a multivariable 
model using a backwards conditional method.  The relationship between a tumor 
microenvironment-based score and survival was further examined using Kaplan-Meier log-
rank analysis, with five-year survival presented as percentage surviving (standard error).  The 
relationship between the tumor microenvironment score and other clinicopathological 
characteristics was examined using χ2 analysis for trend.  A P-value <0.05 was considered 
statistically significant.  All statistical analyses were performed using SPSS version 21.0 
(IBM SPSS, IL, USA).  
  
 
11
RESULTS 
 A total of 307 patients who underwent elective resection for stage I-III colorectal 
adenocarcinoma were included.  Clinicopathological characteristics are summarised in Table 
1.  Two thirds of patients were younger than 75 at time of surgery with a similar number of 
males and females.  The majority of patients (71%) underwent colonic resection, with 
pathological confirmation of lymph node negative (stage I/II) disease in just under two thirds 
of patients.  Venous invasion was detected in 34%, surgical margin involvement in 6%, 
serosal involvement in 25% and tumor perforation in 2% of patients.  A low Klintrup-
Mäkinen grade and high tumor stroma percentage were identified in 66% and 25% of patients 
respectively.  Mismatch repair status was available for 208 patients, with MMR deficient 
colorectal cancer identified in 33 patients (16%).  Overall, 82 patients (27%) received 
adjuvant chemotherapy; 59 patients (52%) with lymph node involvement received adjuvant 
chemotherapy compared to 23 patients (12%) with lymph node negative colorectal cancer. 
 The median follow-up of survivors was 126 months (range 59-194 months), with 95 
cancer-specific deaths.  Five-year cancer specific survival was 75% overall, 86% in patients 
with stage I/II disease and 58% in patients with stage III disease. The relationship between 
clinicopathological and tumor microenvironment characteristics and cancer-specific survival 
are shown in Table 1.  On univariate analysis, advancing age (P<0.05), TNM stage, 
(P<0.001), T stage (P<0.01), N stage, venous invasion (both P<0.001), margin involvement 
(P<0.05), serosal involvement (P=0.001), low Klintrup-Mäkinen grade and high tumor 
stroma percentage (both P=0.001) were all associated with reduced survival.  MMR 
deficiency showed a trend towards increased survival (P=0.082).  On multivariate analysis, 
age, TNM stage (P<0.05), venous invasion (P=0.001), Klintrup-Mäkinen grade (P<0.05) and 
tumor stroma percentage (P<0.01) were independently associated with cancer-specific 
survival. 
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The prognostic value of Klintrup-Mäkinen grade and tumor stroma percentage was 
further examined (Table 2).  Five-year survival of patients with a low tumor stroma 
percentage was 80% (3), whereas patients with a strong Klintrup-Mäkinen grade had five-
year survival of 90%.  The presence of a weak Klintrup-Mäkinen grade or high tumor stroma 
percentage was associated with five-year survival of 68% and 62%, respectively. 
 A cumulative prognostic score based on these characteristics of the tumor 
microenvironment was subsequently derived (Table 2).  As the univariate hazard ratios and 
95% confidence intervals for weak Klintrup-Mäkinen grade and high tumor stroma 
percentage overlapped, the presence of each characteristic scored one point, thus stratifying 
patients into four possible groups.  Patients with a strong Klintrup-Mäkinen grade and low 
tumor stroma percentage comprised 27% of the study population and had a five-year survival 
of 89%; conversely patients with a weak Klintrup-Mäkinen grade and high tumor stroma 
percentage comprised 19% of the group with a four-fold increased risk of cancer-death and 
five-year survival of 51%.  The presence of a weak Klintrup-Mäkinen grade and low tumor 
stroma percentage was identified in almost half of the patients studied and was associated 
with an intermediate five-year survival of 75%.  Only 6% of patients had a strong Klintrup-
Mäkinen grade with a high tumor stroma percentage; this group had an identical five-year 
survival to patients with a strong Klintrup-Mäkinen grade and low tumor stroma percentage.   
As tumor stroma percentage was not associated with survival in patients with a strong 
Klintrup-Mäkinen grade, the cumulative prognostic score was modified to include all patients 
with a strong Klintrup-Mäkinen grade in the good prognostic group, irrespective of tumor 
stroma percentage.  This modified prognostic score, termed the Glasgow Microenvironment 
Score (GMS), stratified patients with primary operable colorectal cancer into three distinct 
prognostic groups (Table 2, Figure 2): a good prognostic group (GMS=0 with a strong 
Klintrup-Mäkinen grade and either high or low tumor stroma percentage) with five-year 
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survival of 89%, an intermediate prognostic group (GMS=1 with a weak Klintrup-Mäkinen 
grade and low tumor stroma percentage) with an almost two-fold increased risk of cancer 
death and five-year survival of 75%, and a poor prognostic group (GMS=3 with a weak 
Klintrup-Mäkinen grade and high tumor stroma percentage) with a four-fold increased risk of 
death and five-year survival of 51%.  Furthermore, on multivariate analysis, GMS was 
associated with reduced survival (HR 1.93, 95% CI 1.36-2.73, P<0.001), independent of 
TNM stage (HR 1.73, 95% CI 1.07-2.80, P=0.025) and venous invasion (HR 2.37, 95% CI 
1.42-3.94, P=0.01).  
The clinical utility of the GMS was further explored in relation to lymph node 
involvement, venous invasion, MMR status and use of adjuvant therapy (Table 3).  GMS 
stratified survival of patients with both lymph node negative (stage I/II) and positive (stage 
III) disease (P=0.036 and P=0.002, respectively) and identified patients with both an 
excellent prognosis (stage I/II and GMS=0, 92% five-year survival) and a poor prognosis 
(stage III and GMS=2, 37% five-year survival).  Furthermore, patients with stage III disease 
and GMS=0 had five-year survival superior to that of patients with stage I/II disease and 
GMS=2 (81% versus 69%).  Similarly, GMS was able to provide further prognostic 
information alongside venous invasion and MMR status; five-year survival of patients 
without venous invasion ranged from 93% to 70% (P=0.025) and with venous invasion from 
78% to 27% (P<0.001), whereas the combination of MMR status and GMS stratified five-
year survival from 100% in patients with MMR deficient colorectal cancer and GMS=0, to 
37% in patients with MMR competent colorectal cancer and GMS=2.  In addition, when 
patients were stratified by use of adjuvant therapy, GMS was predictive of survival of both 
patients who received or did not receive adjuvant chemotherapy (both P=0.002) 
 The relationship between GMS and clinicopathological characteristics was 
subsequently examined (Table 4).  Increasing GMS was associated with use of adjuvant 
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chemotherapy (P<0.05), increasing T stage (P<0.001), N stage, margin and serosal 
involvement (P<0.01), and venous invasion (P<0.05).  GMS was not associated with age, 
sex, tumor site, differentiation, MMR status or the presence of tumor perforation. 
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DISCUSSION 
The present study, for the first time, examines the clinical utility of combined 
assessment of the tumor inflammatory cell infiltrate and tumor stroma, utilising the Klintrup-
Mäkinen grade and tumor stroma percentage respectively, in patients with primary operable 
colorectal cancer.  Indeed, a simple, cumulative prognostic score based on the assessment and 
interaction of these characteristics using routine histopathological specimens and termed the 
Glasgow Microenvironment Score (GMS), was able to provide improved risk stratification.  
Utilising this score, it was possible to identify a group of patients with lymph node negative 
disease with five-year survival comparable to patients with lymph node involvement.  
Conversely, it was also possible to identify patients with stage III disease and five-year 
survival of over 80%.  Similarly, the GMS was able to stratify patients independent of their 
venous invasion and MMR status.  Such a simple, routinely available score can be readily 
evaluated and validated.  If this proves to be the case, then the GMS may help better inform 
decisions regarding the need for adjuvant therapy and surveillance for otherwise “low risk” 
patients, or avoid unnecessary treatment for those previously deemed “high risk”. 
The results of the present study also have profound implications regarding our 
understanding of the nature of the tumor microenvironment.  As survival of patients with a 
strong Klintrup-Mäkinen grade did not differ with tumor stroma percentage, it could be 
inferred that the presence of a strong, conspicuous inflammatory infiltrate represents the 
host’s normal anti-tumor response (12).  Furthermore, few patients had a high tumor stroma 
percentage in the presence of a strong Klintrup-Mäkinen grade.  As such, it may be loss of 
this coordinated immune response that facilitates disease progression, allowing tumor stroma 
formation that in turn facilitates tumor growth and invasion.  Therefore, future work must not 
only consider the intrinsic properties of the tumor cell itself, but also the components of the 
tumor microenvironment.  Indeed, there is increasing evidence that the tumor 
  
 
16
microenvironment may play a role in chemoresistance (17, 23).  Therefore, this new 
knowledge and the GMS, in particular, may be incorporated into future clinical trial design. 
The results of the present study remain to be validated in an independent cohort.  In 
particular, external validation by another research group is required before the GMS can be 
incorporated into routine pathological reporting.  However, given that the GMS utilises routine 
pathological specimens, this will facilitate external validation.  Indeed, assessment of the GMS 
may be readily automated (24, 25), further facilitating validation and the implementation of 
such measures into routine clinical practice. 
The present study is limited by the small number of patients with stage I disease (21 
patients), and as such it was not possible to examine the clinical utility of assessment of the 
tumor microenvironment, or the GMS, for this subgroup of patients separately.  Given that 
earlier, node negative disease is likely to predominate with the introduction of screening (26), 
this would be an important area for further research.  In addition, although the GMS stratified 
survival independent of MMR status, no other prognostic molecular markers were examined.  
To date however, few of these markers have been recommended for use in routine clinical 
practice, and as such their clinical utility in the management of patients with primary 
operable colorectal cancer is yet to be realised (27).   
 In summary, the present study demonstrates the clinical utility of a novel cumulative 
prognostic score based on the tumor inflammatory cell infiltrate and tumor stroma in patients 
with primary operable colorectal cancer.  This score, termed the Glasgow Microenvironment 
Score, has much to commend it since it is simple and routinely available. 
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Figure 1. Assessment of tumor inflammatory cell infiltrate and tumor stroma percentage 
on haematoxylin & eosin–stained sections. A. High Klintrup-Mäkinen grade displaying florid 
cup-like infiltrate at the invasive edge with destruction of cancer cell islands. B. Low 
Klintrup-Mäkinen grade displaying no increase in inflammatory cells at the invasive margin. 
C. Low tumor stroma percentage with less than 10% tumor stroma. D. High tumor stroma 
percentage with approximately 80% tumor stroma. 
 
Figure 2. The relationship between the Glasgow Microenvironment Score and cancer-
specific survival in patients undergoing elective, potentially curative resection of colorectal 
cancer.  Number at risk depicts number of patients alive or not censored entering each time 
period. 
 Table 1. Clinicopathological characteristics and cancer-specific survival in patients undergoing 
elective, potentially curative resection for colorectal cancer 
Clinicopathological characteristics 
(n=307) 
Cancer-specific survival 
 N (%) Univariate HR 
(95% CI) 
P Multivariate HR 
(95% CI) 
P 
Age  
<65 
65-74 
>75 
 
106 (35)a 
106 (35) 
95   (31) 
 
 
 
1.36 (1.05-1.75) 
 
 
 
0.018 
 
 
 
1.36 (1.01-1.84) 
 
 
 
0.043
Sex 
Female 
Male 
 
151 (49) 
156 (51) 
 
 
0.92 (0.61-1.37) 
 
 
0.667 
 
 
- 
 
 
- 
Adjuvant therapy 
No 
Yes 
 
225 (73) 
82   (27) 
 
 
1.26 (0.82-1.95) 
 
 
0.289 
 
 
- 
 
 
- 
Tumour site 
Colon 
Rectum 
 
218 (71) 
89   (29) 
 
 
1.02 (0.65-1.59) 
 
 
0.947 
 
 
- 
 
 
- 
TNM stage 
I 
II 
III 
 
21 (7) 
173 (56) 
113 (37) 
 
 
 
2.31 (1.60-3.35) 
 
 
 
<0.001 
 
 
 
1.69 (1.04-2.74) 
 
 
 
0.034
T stage 
1/2 
3 
4 
 
29   (9) 
196 (64) 
82   (27) 
 
 
 
1.51 (1.12-2.05) 
 
 
 
0.007 
 
 
 
- 
 
 
 
0.855
N stage 
0 
1 
2 
 
194 (63) 
90   (29) 
23   (7) 
 
 
 
1.96 (1.48-2.58) 
 
 
 
<0.001 
 
 
 
- 
 
 
 
0.882
Differentiation 
Mod-well 
Poor 
 
270 (88) 
37  (12) 
 
 
1.60 (0.91-2.83) 
 
 
0.104 
 
 
- 
 
 
- 
Venous invasion 
No 
Yes 
 
203 (66) 
104 (34) 
 
 
2.31 (1.54-3.47) 
 
 
<0.001 
 
 
2.39 (1.43-3.90) 
 
 
0.001
Margin involvement 
No 
Yes 
 
289 (94) 
18   (6) 
 
 
2.42 (1.22-4.82) 
 
 
0.012 
 
 
- 
 
 
0.379
Serosal involvement   
No 
Yes 
 
229 (75) 
78   (25) 
 
 
2.02 (1.33-3.06) 
 
 
0.001 
 
 
- 
 
 
0.246
Tumour perforation  
No 
Yes 
 
300  (98) 
7      (2) 
 
 
2.47 (0.78-7.84) 
 
 
0.126 
 
 
- 
 
 
- 
Mismatch repair (n=208) 
Competent 
Deficient 
 
175 (84) 
33 (16) 
 
 
0.47 (0.21-1.10) 
 
 
0.082 
 
 
- 
 
 
0.319
Klintrup-Mäkinen grade 
Strong 
Weak 
 
103  (34) 
204  (66) 
 
 
2.42 (1.47-4.01) 
 
 
0.001 
 
 
2.00 (1.10-3.63) 
 
 
0.022
Tumour stroma percentage 
Low 
High 
 
231 (75) 
76   (25) 
 
 
2.05 (1.35-3.12) 
 
 
0.001 
 
 
2.14 (1.28-3.57) 
 
 
0.004
a-total may not equal 100% as rounded to nearest whole number, 95% CI – 95% confidence interval, 
 
Table 2. Relationship between Klintrup-Mäkinen grade, tumor stroma 
percentage and cancer-specific survival in patients undergoing elective, 
potentially curative resection of colorectal cancer 
Tumor microenvironment 
characteristic 
N 5-year CSS % 
(SE) 
Univariate HR 
(95% CI) 
P 
K-M grade 
Strong 
Weak 
 
103 
204
 
90 (3) 
68 (3) 
 
- 
- 
 
- 
- 
TSP 
Low 
High 
 
231 
76 
 
80 (3) 
62 (6) 
 
- 
- 
 
- 
- 
Combined K-M grade/ TSP 
0 (K-M strong/ low TSP) 
1 (K-M strong/ high TSP) 
1 (K-M weak/ low TSP) 
2 (K-M weak/ high TSP) 
 
84 
19 
147 
57 
 
89 (4) 
89 (7) 
75 (4) 
51 (7) 
 
1 
1.23 (0.41-3.71) 
2.00 (1.12-3.58) 
4.25 (2.28-7.92) 
 
- 
0.715 
0.020 
<0.001 
Glasgow Microenvironment 
Score 
0 (K-M strong) 
1 (K-M weak/ low TSP) 
2 (K-M weak/ high TSP) 
 
 
103 
147 
57 
 
 
89 (3) 
75 (4) 
51 (7) 
 
 
1 
1.92 (1.13-3.28) 
4.08 (2.29-7.27) 
 
 
- 
0.017 
<0.001 
CSS – cancer-specific survival, SE – standard error, HR – hazard ratio, K-M – 
Klintrup-Mäkinen grade, TSP –tumor stroma percentage 
 
Table 3. The relationship between Glasgow Microenvironment Score, lymph node status, venous invasion, mismatch repair status and 
adjuvant chemotherapy and 5-year cancer-specific survival in patients undergoing elective, potentially curative resection of colorectal 
cancer resection  
 Glasgow Microenvironment Score  
 0 1 2 P All patients 
 N 5-yr survival % 
(SE) 
N 5-yr survival % 
(SE) 
N 5-yr survival %  
(SE) 
 N 5-yr survival % 
(SE) 
(n=307)          
Lymph node status          
Negative 70  92 (3) 99  84 (4) 25 69 (10) 0.036 173 86 (3) 
Positive 33 81 (7) 48 55 (7) 32 37 (9) 0.002 113 58 (5) 
          
Venous invasion 
Absent 
 
74 
 
93 (3) 
 
98 
 
77 (4) 
 
31
 
70 (8) 
 
0.025 
 
203
 
82 (3) 
Present 29 78 (8) 49 70 (7) 26 27 (9) <0.001 104 62 (5) 
          
No adjuvant therapy 79 90 (3) 112 73 (4) 34 58 (9) 0.002 225 76 (3) 
Adjuvant therapy 24 87 (7) 35 81 (7) 23 43 (10) 0.002 82 72 (5) 
          
All patients  103  89 (3) 147 75 (4) 57 51 (7) <0.001 307 75 (3) 
(n=208)          
MMR status          
MMR deficient 13 100 (0) 15 67 (12) 5 - <0.001 33 84 (7) 
MMR competent 59 84 (5) 81 76 (5) 35 37 (9) 0.094 175 71 (4) 
          
All patients  72 87 (4) 96 75 (5) 40 45 (8) <0.001 208 73 (3) 
SE – standard error, MMR – mismatch repair 
Table 4. The relationship between Glasgow Microenvironment Score, and 
clinicopathological characteristics in patients undergoing elective, potentially 
curative resection of colorectal cancer  
Clinicopathological characteristics N (%) 
 Glasgow Microenvironment Score 
 0 (n=103) 1 (n=147) 2 (n=57) P 
Age       
<65 
65-74 
>75 
 
36 (35)a 
39 (38) 
28 (27) 
 
47 (32) 
50 (34) 
50 (34) 
 
23 (40) 
17 (30) 
17 (30) 
 
0.972 
Sex       
Female 
Male 
 
51 (50) 
52 (51) 
 
77 (52) 
70 (48) 
 
23 (40) 
34 (60) 
0.386 
Adjuvant therapy       
No 
Yes 
 
79 (77) 
24 (23) 
 
112 (76) 
35 (24) 
 
34 (60) 
23 (40) 
0.040 
Tumor site 
Colon 
Rectum 
 
74 (72) 
29 (28) 
 
104 (71) 
43 (29) 
 
40 (70) 
17 (30) 
0.812 
T stage 
1/2 
3 
4 
 
19 (18) 
63 (61) 
21 (20) 
 
9 (6) 
105 (71) 
33 (22) 
 
1 (2) 
28 (49) 
28 (49) 
<0.001 
N stage 
0 
1 
2 
 
70 (68) 
29 (28) 
4 (4) 
 
99 (67) 
36 (25) 
12 (8) 
 
25 (44) 
25 (44) 
7 (12) 
0.004 
Differentiation 
Mod-well 
Poor 
 
90 (87) 
13 (13) 
 
131 (89) 
16 (11) 
 
49 (86) 
8 (14) 
0.893 
Mismatch repair status 
Competent 
Deficient 
 
59 (82) 
13 (18) 
 
81 (84) 
15 (16) 
 
35 (88) 
5 (13) 
0.441 
Margin involvement 
No 
Yes 
 
101 (98) 
2 (2) 
 
139 (95) 
8 (5) 
 
49 (86) 
8 (14) 
0.003 
Serosal involvement   
No 
Yes 
 
83 (81) 
20 (19) 
 
113 (77) 
34 (23) 
 
33 (58) 
24 (42) 
0.004 
Tumor perforation  
No 
Yes 
 
101 (98) 
2 (2) 
 
143 (97) 
4 (3) 
 
56 (98) 
1 (2) 
0.979 
Venous invasion 
No 
Yes 
 
74 (72) 
29 (28) 
 
98 (67) 
49 (33) 
 
31 (54) 
26 (46) 
0.032 
a-total may not equal 100% as rounded to nearest whole number. 


